



Short Review



RIFM fragrance ingredient safety assessment, guaiacyl phenylacetate, CAS Registry Number 4112-89-4

A.M. Api^a, D. Belsito^b, D. Botelho^a, M. Bruze^c, G.A. Burton Jr.^d, M.A. Cancellieri^a, H. Chon^a, M.L. Dagli^e, W. Dekant^f, C. Deodhar^a, A.D. Fryer^g, L. Jones^a, K. Joshi^a, M. Kumar^a, A. Lapczynski^a, M. Lavelle^a, I. Lee^a, D.C. Liebler^h, H. Moustakas^a, M. Na^a, T.M. Penningⁱ, G. Ritacco^a, J. Romine^a, N. Sadekar^a, T.W. Schultz^j, D. Selechnik^a, F. Siddiqi^a, I.G. Sipes^k, G. Sullivan^{a,*}, Y. Thakkar^a, Y. Tokura^l

^a Research Institute for Fragrance Materials, Inc., 50 Tice Boulevard, Woodcliff Lake, NJ, 07677, USA

^b Member Expert Panel for Fragrance Safety, Columbia University Medical Center, Department of Dermatology, 161 Fort Washington Ave., New York, NY, 10032, USA

^c Member Expert Panel for Fragrance Safety, Malmö University Hospital, Department of Occupational & Environmental Dermatology, Sodra Forstadsgatan 101, Entrance 47, Malmö, SE, 20502, Sweden

^d Member Expert Panel for Fragrance Safety, School of Natural Resources & Environment, University of Michigan, Dana Building G110, 440 Church St., Ann Arbor, MI, 48109, USA

^e Member Expert Panel for Fragrance Safety, University of Sao Paulo, School of Veterinary Medicine and Animal Science, Department of Pathology, Av. Prof. dr. Orlando Marques de Paiva, 87, Sao Paulo, CEP 05508-900, Brazil

^f Member Expert Panel for Fragrance Safety, University of Würzburg, Department of Toxicology, Versbacher Str. 9, 97078, Würzburg, Germany

^g Member Expert Panel for Fragrance Safety, Oregon Health & Science University, 3181 SW Sam Jackson Park Rd., Portland, OR, 97239, USA

^h Member Expert Panel for Fragrance Safety, Vanderbilt University School of Medicine, Department of Biochemistry, Center in Molecular Toxicology, 638 Robinson Research Building, 2200 Pierce Avenue, Nashville, TN, 37232-0146, USA

ⁱ Member of Expert Panel for Fragrance Safety, University of Pennsylvania, Perelman School of Medicine, Center of Excellence in Environmental Toxicology, 1316 Biomedical Research Building (BRB) II/III, 421 Curie Boulevard, Philadelphia, PA, 19104-3083, USA

^j Member Expert Panel for Fragrance Safety, The University of Tennessee, College of Veterinary Medicine, Department of Comparative Medicine, 2407 River Dr., Knoxville, TN, 37996-4500, USA

^k Member Expert Panel for Fragrance Safety, Department of Pharmacology, University of Arizona, College of Medicine, 1501 North Campbell Avenue, P.O. Box 245050, Tucson, AZ, 85724-5050, USA


^l Member Expert Panel for Fragrance Safety, The Journal of Dermatological Science (JDS), Editor-in-Chief, Professor and Chairman, Department of Dermatology, Hamamatsu University School of Medicine, 1-20-1 Handayama, Higashi-ku, Hamamatsu, 431-3192, Japan

ARTICLE INFO

Handling Editor: Dr. Bryan Delaney

Version: 101022. Initial publication. All fragrance materials are evaluated on a five-year rotating basis. Revised safety assessments are published if new relevant data become available. Open access to all RIFM Fragrance Ingredient Safety Assessments is here: fragrancesafetyresource.elsevier.com.

Name: Guaiacyl phenylacetate CAS
Registry Number: 4112-89-4



(continued on next column)

(continued)

Abbreviation/Definition List:

2-Box Model - A RIFM, Inc. proprietary *in silico* tool used to calculate fragrance air exposure concentration

AF - Assessment Factor

BCF - Bioconcentration Factor

CNIH - Confirmation of No Induction in Humans test. A human repeat insult patch test that is performed to confirm an already determined safe use level for fragrance ingredients (Na et al., 2021)

Creme RIFM Model - The Creme RIFM Model uses probabilistic (Monte Carlo) simulations to allow full distributions of data sets, providing a more realistic

(continued on next page)

* Corresponding author.

E-mail address: gsullivan@rifm.org (G. Sullivan).

<https://doi.org/10.1016/j.fct.2023.113622>

Received 11 October 2022; Received in revised form 6 December 2022; Accepted 13 January 2023

Available online 16 January 2023

0278-6915/© 2023 Elsevier Ltd. All rights reserved.

(continued)

estimate of aggregate exposure to individuals across a population (Comiskey et al., 2015, 2017; Safford et al., 2015a, 2017) compared to a deterministic aggregate approach

DEREK - Derek Nexus is an *in silico* tool used to identify structural alerts

DRF - Dose Range Finding

DST - Dermal Sensitization Threshold

ECHA - European Chemicals Agency

ECOSAR - Ecological Structure-Activity Relationships Predictive Model

EU - Europe/European Union

GLP - Good Laboratory Practice

IFRA - The International Fragrance Association

LOEL - Lowest Observed Effect Level

MOE - Margin of Exposure

MPPD - Multiple-Path Particle Dosimetry. An *in silico* model for inhaled vapors used to simulate fragrance lung deposition

NA - North America

NESIL - No Expected Sensitization Induction Level

NOAEC - No Observed Adverse Effect Concentration

NOAEL - No Observed Adverse Effect Level

NOEC - No Observed Effect Concentration

NOEL - No Observed Effect Level

OECD - Organisation for Economic Co-operation and Development

OECD TG - Organisation for Economic Co-operation and Development Testing Guidelines

PBT - Persistent, Bioaccumulative, and Toxic

PEC/PNEC - Predicted Environmental Concentration/Predicted No Effect Concentration

Perfumery - In this safety assessment, perfumery refers to fragrances made by a perfumer used in consumer products only. The exposures reported in the safety assessment include consumer product use but do not include occupational exposures.

QRA - Quantitative Risk Assessment

QSAR - Quantitative Structure-Activity Relationship

REACH - Registration, Evaluation, Authorisation, and Restriction of Chemicals

RfD - Reference Dose

RIFM - Research Institute for Fragrance Materials

RQ - Risk Quotient

Statistically Significant - Statistically significant difference in reported results as compared to controls with a $p < 0.05$ using appropriate statistical test

TTC - Threshold of Toxicological Concern

UV/Vis spectra - Ultraviolet/Visible spectra

VCF - Volatile Compounds in Food

VoU - Volume of Use

vPvB - (very) Persistent, (very) Bioaccumulative

WoE - Weight of Evidence

The Expert Panel for Fragrance Safety* concludes that this material is safe as described in this safety assessment.

This safety assessment is based on the RIFM Criteria Document (Api et al., 2015), which should be referred to for clarifications. Each endpoint discussed in this safety assessment includes the relevant data that were available at the time of writing (version number in the top box is indicative of the date of approval based on a 2-digit month/day/year), both in the RIFM Database (consisting of publicly available and proprietary data) and through publicly available information sources (e.g., SciFinder and PubMed). Studies selected for this safety assessment were based on appropriate test criteria, such as acceptable guidelines, sample size, study duration, route of exposure, relevant animal species, most relevant testing endpoints, etc. A key study for each endpoint was selected based on the most conservative endpoint value (e.g., PNEC, NOAEL, LOEL, and NESIL).

*The Expert Panel for Fragrance Safety is an independent body that selects its own members and establishes its own operating procedures. The Expert Panel is comprised of internationally known scientists that provide RIFM with guidance relevant to human health and environmental protection.

Summary: The existing information supports the use of this material as described in this safety assessment.

Guaiacyl phenylacetate was evaluated for genotoxicity, repeated dose toxicity, reproductive toxicity, local respiratory toxicity, photoirritation/photoallergenicity, skin sensitization, and environmental safety. Data from read-across analogs guaiacol (CAS # 90-05-1), phenylacetic acid (CAS # 103-82-2), and 2-hydroxyphenylacetic acid (CAS # 614-75-5) show that guaiacyl phenylacetate is not expected to be genotoxic. The repeated dose, reproductive, and local respiratory toxicity endpoints were evaluated using the Threshold of Toxicological Concern (TTC) for a Cramer Class I material, and the exposure to guaiacyl phenylacetate is below the TTC (0.03 mg/kg/day, 0.03 mg/kg/day, and 1.4 mg/day, respectively). The skin sensitization endpoint was completed using the Dermal Sensitization Threshold (DST) for reactive materials (64 $\mu\text{g}/\text{cm}^2$); exposure is below the DST. The photoirritation/photoallergenicity endpoints were evaluated based on ultraviolet/

(continued on next column)

(continued)

visible (UV/Vis) spectra; guaiacyl phenylacetate is not expected to be photoirritating/photoallergenic. The environmental endpoints were evaluated; guaiacyl phenylacetate was found not to be Persistent, Bioaccumulative, and Toxic (PBT) as per the International Fragrance Association (IFRA) Environmental Standards, and its risk quotients, based on its current volume of use (VoU) in Europe and North America (i.e., Predicted Environmental Concentration/Predicted No Effect Concentration [PEC/PNEC]), are < 1 .

Human Health Safety Assessment

Genotoxicity: Not expected to be genotoxic. (ECHA REACH Dossier: Guaiacol; ECHA, 2011; RIFM, 1983; RIFM, 1993)

Repeated Dose Toxicity: No NOAEL available. Exposure is below the TTC.

Reproductive Toxicity: No NOAEL available. Exposure is below the TTC.

Skin Sensitization: Not a concern for skin sensitization under the declared use levels; exposure is below the DST.

Photoirritation/Photoallergenicity: Not expected to be photoirritating/photoallergenic. (UV/Vis Spectra; RIFM Database)

Local Respiratory Toxicity: No NOAEC available. Exposure is below the TTC.

Environmental Safety Assessment

Hazard Assessment:

Persistence: Screening-level: 2.7 (EPI Suite v4.11; US EPA, 2012a) (BIOWIN 3)

Bioaccumulation: Screening-level: 78.73 L/kg (EPI Suite v4.11; US EPA, 2012a)

Ecotoxicity: Screening-level: Fish LC50: 20.59 mg/L (RIFM Framework; Salvito et al., 2002)

Conclusion: Not PBT or vPvB as per IFRA Environmental Standards

Risk Assessment:

Screening-level: PEC/PNEC (North America and Europe) < 1 (RIFM Framework; Salvito et al., 2002)

Critical Ecotoxicity Endpoint: Fish LC50: 20.59 mg/L (RIFM Framework; Salvito et al., 2002)

RIFM PNEC is: 0.02059 $\mu\text{g}/\text{L}$

• **Revised PEC/PNECs (2019 IFRA VoU):** North America and Europe: Not applicable; cleared at screening-level

1. Identification

- 1. Chemical Name:** Guaiacyl phenylacetate
- 2. CAS Registry Number:** 4112-89-4
- 3. Synonyms:** Benzeneacetic acid, 2-methoxyphenyl ester; Guaiacol phenylacetate; o-Methoxyphenyl phenylacetate; 2-Methoxyphenyl phenylacetate; o-Methylcatechol phenylacetate; Guaiacyl phenylacetate
- 4. Molecular Formula:** $\text{C}_{15}\text{H}_{14}\text{O}_3$
- 5. Molecular Weight:** 242.27 g/mol
- 6. RIFM Number:** 5047
- 7. Stereochemistry:** No stereocenter present and no stereoisomer possible.

2. Physical data

- 1. Boiling Point:** 343.61 °C (EPI Suite)
- 2. Flash Point:** > 200 °F; CC (Fragrance Materials Association [FMA])
- 3. Log K_{ow} :** 3.38 (EPI Suite)
- 4. Melting Point:** 38 °C (FMA), 101.27 °C (EPI Suite)
- 5. Water Solubility:** 33.99 mg/L (EPI Suite)
- 6. Specific Gravity:** Not Available
- 7. Vapor Pressure:** 0.0000167 mm Hg at 20 °C (EPI Suite v4.0), 3.38e-005 mm Hg at 25 °C (EPI Suite)
- 8. UV Spectra:** No absorbance between 290 and 700 nm; molar absorption coefficient is below the benchmark (1000 $\text{L mol}^{-1} \cdot \text{cm}^{-1}$)
- 9. Appearance/Organoleptic:** Not Available

3. Volume of use (worldwide band)

1. <0.1 metric ton per year (IFRA, 2019)

4. Exposure to fragrance ingredient (Creme RIFM aggregate exposure model v3.2.6)

1. **95th Percentile Concentration in Fine Fragrance:** 0.00013% (RIFM, 2022)
2. **Inhalation Exposure*:** <0.0001 mg/kg/day or 0.0000028 mg/day (RIFM, 2022)
3. **Total Systemic Exposure**:** 0.00025 mg/kg/day (RIFM, 2022)

*95th percentile calculated exposure derived from concentration survey data in the Creme RIFM Aggregate Exposure Model (Comiskey, 2015; Safford, 2015a; Safford, 2017; and Comiskey et al., 2017).

**95th percentile calculated exposure; assumes 100% absorption unless modified by dermal absorption data as reported in Section V. It is derived from concentration survey data in the Creme RIFM Aggregate Exposure Model and includes exposure via dermal, oral, and inhalation routes whenever the fragrance ingredient is used in products that include these routes of exposure (Comiskey, 2015; Safford, 2015a; Safford, 2017; and Comiskey et al., 2017).

5. Derivation of systemic absorption

1. **Dermal:** Assumed 100%
2. **Oral:** Assumed 100%
3. **Inhalation:** Assumed 100%

6. Computational toxicology evaluation

1. Cramer Classification: Class I, Low

Expert Judgment	Toxtree v3.1	OECD QSAR Toolbox v4.5
I	I	I

2. Analogs Selected:

- a. **Genotoxicity:** Guaiacol (CAS # 90-05-1), phenylacetic acid (CAS # 103-82-2), 2-hydroxyphenylacetic acid (CAS # 614-75-5)
 - b. **Repeated Dose Toxicity:** None
 - c. **Reproductive Toxicity:** None
 - d. **Skin Sensitization:** None
 - e. **Photoirritation/Photoallergenicity:** None
 - f. **Local Respiratory Toxicity:** None
 - g. **Environmental Toxicity:** None
3. Read-across Justification: See Appendix below

7. Metabolism

No relevant data available for inclusion in this safety assessment.
Additional References: None.

8. Natural occurrence

Guaiacyl phenylacetate is not reported to occur in foods by the VCF*.

*VCF Volatile Compounds in Food: Database/Nijssen, L.M.; Ingen-Visscher, C.A. van; Donders, J.J.H. (eds). – Version 15.1 – Zeist (The Netherlands): TNO Triskelion, 1963–2014. A continually updated database containing information on published volatile compounds that have been found in natural (processed) food products. Includes FEMA GRAS and EU-Flavis data.

9. REACH dossier

Guaiacyl phenylacetate has been pre-registered for 2010; no dossier available as of 10/10/22.

10. Conclusion

The existing information supports the use of this material as described in this safety assessment.

11. Summary

11.1. Human health endpoint summaries

11.1.1. Genotoxicity

Based on the current existing data, guaiacyl phenylacetate does not present a concern for genotoxicity.

There are no studies assessing the mutagenic or clastogenic activity of guaiacyl phenylacetate; however, read-across can be made to guaiacol, phenylacetic acid, and 2-hydroxyphenylacetic acid (CAS # 90-05-1, 103-82-2, and 614-75-5, respectively; see Section VI).

The mutagenic activity of guaiacol has been evaluated in a bacterial reverse mutation assay conducted in an equivalent manner to OECD TG 471 using the standard plate incorporation method. *Salmonella typhimurium* strains TA98, TA100, TA1535, TA1537, and TA1538 were treated with guaiacol in dimethyl sulfoxide (DMSO) at concentrations up to 5000 µg/plate. No increases in the mean number of revertant colonies were observed at any tested concentration in the presence or absence of S9 (ECHA, 2011). Under the conditions of the study, guaiacol was not mutagenic in the Ames test, and this can be extended to guaiacyl phenylacetate.

The mutagenic activity of phenylacetic acid has been evaluated in a bacterial reverse mutation assay conducted in compliance with GLP regulations and in accordance with OECD TG 471 using the standard plate incorporation method. *Salmonella typhimurium* strains TA98, TA100, TA1535, TA1537, and TA1538 were treated with phenylacetic acid in DMSO at concentrations up to 10000 µg/plate. No increases in the mean number of revertant colonies were observed at any tested concentration in the presence or absence of S9 (RIFM, 1983). Under the conditions of the study, phenylacetic acid was not mutagenic in the Ames test, and this can be extended to guaiacyl phenylacetate.

The clastogenic activity of guaiacol was evaluated in an *in vivo* micronucleus test conducted in compliance with GLP regulations and in accordance with OECD TG 474. The test material was administered in corn oil via oral gavage to groups of male and female NMRI mice. Doses of 125, 250, or 500 mg/kg were administered. Mice from each dose level were euthanized at 24 and 48 h, and the bone marrow was extracted and examined for polychromatic erythrocytes. The test material did not induce a statistically significant increase in the incidence of micronucleated polychromatic erythrocytes in the bone marrow (ECHA, 2011). Under the conditions of the study, guaiacol was considered to be not clastogenic in the *in vivo* micronucleus test, and this can be extended to guaiacyl phenylacetate.

The clastogenicity of 2-hydroxyphenylacetic acid was assessed in an *in vitro* chromosome aberration study conducted in compliance with GLP regulations and in accordance with OECD TG 473. Chinese hamster ovary cells were treated with 2-hydroxyphenylacetic acid in DMSO at concentrations up to 5000 µg/mL in the dose range finding (DRF) study; the main study was conducted at concentrations up to 5000 µg/mL in the presence and absence of metabolic activation. No statistically significant increases in the frequency of cells with structural chromosomal aberrations or polyploid cells were observed with any concentration of the test material, either with or without S9 metabolic activation (RIFM,

1993). Under the conditions of the study, 2-hydroxyphenylacetic acid was considered to be non-clastogenic in the *in vitro* chromosome aberration assay, and this can be extended to guaiacyl phenylacetate.

Based on the data available, guaiacol does not present a concern for genotoxic potential.

Additional References: None.

Literature Search and Risk Assessment Completed On: 05/20/22.

11.1.2. Repeated dose toxicity

There are no repeated dose toxicity data on guaiacyl phenylacetate or any read-across materials. The total systemic exposure to guaiacyl phenylacetate is below the TTC for the repeated dose toxicity endpoint of a Cramer Class I material at the current level of use.

11.1.2.1. Risk assessment. There are no repeated dose toxicity data on guaiacyl phenylacetate or any read-across materials that can be used to support the repeated dose toxicity endpoint. The total systemic exposure to guaiacyl phenylacetate (0.25 µg/kg/day) is below the TTC (30 µg/kg/day; Kroes et al., 2007) for the repeated dose toxicity endpoint of a Cramer Class I material at the current level of use.

Additional References: None.

Literature Search and Risk Assessment Completed On: 03/15/22.

11.1.3. Reproductive toxicity

There are no reproductive toxicity data on guaiacyl phenylacetate or on any read-across materials. The total systemic exposure to guaiacyl phenylacetate is below the TTC for the reproductive toxicity endpoint of a Cramer Class I material at the current level of use.

11.1.3.1. Risk assessment. There are no reproductive toxicity data on guaiacyl phenylacetate or on any read-across materials that can be used to support the reproductive toxicity endpoint. The total systemic exposure to guaiacyl phenylacetate (0.25 µg/kg/day) is below the TTC (30 µg/kg/day; Kroes et al., 2007; Laufersweiler et al., 2012) for the reproductive toxicity endpoint of a Cramer Class I material at the current level of use.

Additional References: None.

Literature Search and Risk Assessment Completed On: 03/15/22.

11.1.4. Skin sensitization

Based on existing data and the application of DST, guaiacyl phenylacetate does not present a safety concern for skin sensitization under the current declared levels of use.

11.1.4.1. Risk assessment. Limited skin sensitization data are available for guaiacyl phenylacetate (see Table 1 below). The chemical structure of this material indicates that it would not be expected to react with skin proteins directly, while its metabolite is expected to be reactive (Roberts et al., 2007; OECD Toolbox v4.5). Acting conservatively due to the limited data, the reported exposure was benchmarked utilizing the reactive DST of 64 µg/cm² (Safford, 2008; Safford, 2011; Roberts et al., 2015; Safford, 2015b). The current exposure from the 95th percentile concentration is below the DST for reactive materials when evaluated in all QRA categories. Table 2 provides the supported concentrations for guaiacyl phenylacetate that present no appreciable risk for skin sensitization based on the reactive DST. These levels represent supported concentrations based on the DST approach. However, additional studies may show it could be used at higher levels.

Additional References: None.

Literature Search and Risk Assessment Completed On: 05/04/22.

11.1.5. Photoirritation/photoallergenicity

Based on the available UV/Vis spectra, guaiacyl phenylacetate would not be expected to present a concern for photoirritation or photoallergenicity.

11.1.5.1. Risk assessment. There are no photoirritation studies available for guaiacyl phenylacetate in experimental models. UV/Vis absorption spectra indicate no absorption between 290 and 700 nm. The corresponding molar absorption coefficient is below the benchmark of concern for photoirritation and photoallergenicity (Henry et al., 2009). Based on the lack of absorbance, guaiacyl phenylacetate does not present a concern for photoirritation or photoallergenicity.

11.1.5.2. UV spectra analysis. UV/Vis absorption spectra (OECD TG 101) were obtained. The spectra indicate no absorbance in the range of 290–700 nm. The molar absorption coefficient is below the benchmark of concern for photoirritating effects, 1000 L mol⁻¹ • cm⁻¹ (Henry et al., 2009).

Additional References: None.

Literature Search and Risk Assessment Completed On: 04/12/22.

Table 1

Summary of existing data on guaiacyl phenylacetate.

WoE Skin Sensitization Potency Category ^a	Human Data				Animal Data		
	NOEL-CNIH (induction) µg/cm ²	NOEL-HMT (induction) µg/cm ²	LOEL ^b (induction) µg/cm ²	WoE NESIL ^c µg/cm ²	LLNA ^d Weighted Mean EC3 Value µg/cm ²	GPMT ^e	Buehler ^e
Sensitizer; Human potency category unknown; Current exposure level below the DST for reactive materials.	NA	NA	NA	NA	NA	NA	NA
	<i>In vitro</i> Data^f				<i>In silico</i> protein binding alerts (OECD Toolbox v4.5)		
	KE 1	KE 2	KE 3	Target Material	Autoxidation simulator	Metabolism simulator	
	NA	NA	NA	No alert found	No alert found	Schiff base formation	

NOEL = No observed effect level; CNIH = Confirmation of No Induction in Humans test; HMT = Human Maximization Test; LOEL = lowest observed effect level; KE = Key Event; NA = Not Available.

^a WoE Skin Sensitization Potency Category is only applicable for identified sensitizers with sufficient data, based on collective consideration of all available data (Na et al., 2021).

^b Data derived from CNIH or HMT.

^c WoE NESIL limited to 2 significant figures.

^d Based on animal data using classification defined in ECETOC, Technical Report No. 87, 2003.

^e Studies conducted according to the OECD TG 406 are included in the table.

^f Studies conducted according to the OECD TG 442, Cottrez et al. (2016), or Forreryd et al. (2016) are included in the table.

Table 2

Supported concentrations for guaiacyl phenylacetate that present no appreciable risk for skin sensitization based on reactive DST.

IFRA Category ^a	Description of Product Type	Supported Concentrations ^b (%) in Finished Products Based on Reactive DST	Reported 95th Percentile Use Concentrations in Finished Products
1	Products applied to the lips	0.0049	NRU ^c
2	Products applied to the axillae	0.0015	2.5×10^{-5}
3	Products applied to the face using fingertips	0.029	2.1×10^{-6}
4	Fine fragrance products	0.027	1.3×10^{-4}
5	Products applied to the face and body using the hands (palms), primarily leave-on	0.0070	2.5×10^{-5}
6	Products with oral and lip exposure	0.016	NRU ^c
7	Products applied to the hair with some hand contact	0.056	4.2×10^{-6}
8	Products with significant anogenital exposure	0.0029	No Data ^d
9	Products with body and hand exposure, primarily rinse-off	0.054	1.2×10^{-5}
10	Household care products with mostly hand contact	0.19	NRU ^c
11	Products with intended skin contact but minimal transfer of fragrance to skin from inert substrate	0.11	No Data ^d
12	Products not intended for direct skin contact, minimal or insignificant transfer to skin	Not restricted	NRU ^c

Note.

^a For a description of the categories, refer to the IFRA/RIFM Information Booklet.

^b These levels represent supported concentrations based on the DST. However, additional studies may show it could be used at higher levels.

^c No reported use.

^d Fragrance exposure from these products is very low. These products are not currently in the Creme RIFM Aggregate Exposure Model.

11.1.6. Local Respiratory Toxicity

The MOE could not be calculated due to a lack of appropriate data. The exposure level for guaiacyl phenylacetate is below the Cramer Class I TTC value for inhalation exposure local effects.

11.1.6.1. Risk assessment. There are no inhalation data available on guaiacyl phenylacetate. Based on the Creme RIFM Model, the inhalation exposure is 0.0000028 mg/day. This exposure is 500000 times lower than the Cramer Class I TTC value of 1.4 mg/day (based on human lung weight of 650 g; Carthew et al., 2009); therefore, the exposure at the current level of use is deemed safe.

Additional References: None.

Literature Search and Risk Assessment Completed On: 05/19/22.

11.2. Environmental endpoint summary

11.2.1. Screening-level assessment

A screening-level risk assessment of guaiacyl phenylacetate was performed following the RIFM Environmental Framework (Salvito, 2002), which provides 3 tiered levels of screening for aquatic risk. In Tier 1, only the material's regional VoU, its log K_{ow} , and its molecular weight are needed to estimate a conservative risk quotient (RQ), expressed as the ratio Predicted Environmental Concentration/Predicted No Effect Concentration (PEC/PNEC). A general QSAR with a high uncertainty factor applied is used to predict fish toxicity, as discussed in Salvito et al. (2002). In Tier 2, the RQ is refined by applying a lower uncertainty factor to the PNEC using the ECOSAR model (US EPA, 2012b), which provides chemical class-specific ecotoxicity estimates. Finally, if necessary, Tier 3 is conducted using measured biodegradation and ecotoxicity data to refine the RQ, thus allowing for lower PNEC uncertainty factors. The data for calculating the PEC and PNEC for this safety assessment are provided in the table below. For the PEC, the range from the most recent IFRA VoU Survey is reviewed. The PEC is then calculated using the actual regional tonnage, not the extremes of the range. Following the RIFM Environmental Framework, guaiacyl phenylacetate was identified as a fragrance material with no potential to present a possible risk to the aquatic environment (i.e., its screening-level PEC/PNEC <1).

A screening-level hazard assessment using EPI Suite v4.11 (US EPA, 2012a) did not identify guaiacyl phenylacetate as possibly persistent or bioaccumulative based on its structure and physical-chemical properties. This screening-level hazard assessment considers the potential for a material to be persistent *and* bioaccumulative *and* toxic, or very persistent *and* very bioaccumulative, as defined in the Criteria Document (Api, 2015). As noted in the Criteria Document, the screening criteria applied are the same as those used in the EU for REACH (ECHA, 2017a). For persistence, if the EPI Suite model BIOWIN 3 predicts a value < 2.2 and either BIOWIN 2 or BIOWIN 6 predicts a value < 0.5, then the material is considered potentially persistent. A material would be considered potentially bioaccumulative if the EPI Suite model BCFBAF predicts a fish BCF ≥ 2000 L/kg. Ecotoxicity is determined in the above screening-level risk assessment. If, based on these model outputs (Step 1), additional assessment is required, a WoE-based review is then performed (Step 2). This review considers available data on the material's physical-chemical properties, environmental fate (e.g., OECD Guideline biodegradation studies or die-away studies), fish bioaccumulation, and higher-tier model outputs (e.g., US EPA's BIOWIN and BCFBAF found in EPI Suite v4.11).

11.2.2. Risk assessment

Based on the current VoU (2019), guaiacyl phenylacetate presents no risk to the aquatic compartment in the screening-level assessment.

11.2.3. Key studies

11.2.3.1. Biodegradation. No data available.

11.2.3.2. Ecotoxicity. No data available.

11.2.3.3. Other available data. Guaiacyl phenylacetate has been pre-registered for REACH, with no additional data available at this time.

11.2.3.3.1. Risk assessment refinement. Ecotoxicological data and PNEC derivation (all endpoints reported in mg/L; PNECs in $\mu\text{g/L}$)

Endpoints used to calculate PNEC are underlined.

Exposure information and PEC calculation (following RIFM Environmental Framework: Salvito et al., 2002)

	LC50 (Fish) (mg/L)	EC50 (<i>Daphnia</i>) (mg/L)	EC50 (Algae) (mg/L)	AF	PNEC (µg/L)	Chemical Class
RIFM Framework Screening-level (Tier 1)	20.59			1000000	0.02059	

Exposure	Europe (EU)	North America (NA)
Log K_{ow} Used	3.38	3.38
Biodegradation Factor Used	0	0
Dilution Factor	3	3
Regional VoU Tonnage Band	<1	<1
Risk Characterization: PEC/PNEC	<1	<1

Based on available data, the RQ for this material is < 1. No further assessment is necessary.

The RIFM PNEC is 0.02059 µg/L. The revised PEC/PNECs for EU and NA are not applicable. The material was cleared at the screening-level; therefore, it does not present a risk to the aquatic environment at the current reported volumes of use.

Literature Search and Risk Assessment Completed On: 05/15/22.

12. Literature Search*

- **RIFM Database:** Target, Fragrance Structure-Activity Group materials, other references, JECFA, CIR, SIDS
- **ECHA:** <https://echa.europa.eu/>
- **NTP:** <https://ntp.niehs.nih.gov/>
- **OECD Toolbox:** <https://www.oecd.org/chemicalsafety/risk-assessment/oecd-qsar-toolbox.htm>
- **SciFinder:** <https://scifinder.cas.org/scifinder/view/scifinder/scifinderExplore.jsf>
- **PubChem:** <https://pubchem.ncbi.nlm.nih.gov/>
- **PubMed:** <https://www.ncbi.nlm.nih.gov/pubmed>

Appendix A. Supplementary data

Supplementary data to this article can be found online at <https://doi.org/10.1016/j.fct.2023.113622>.

Appendix

Read-across Justification

Methods

The read-across analogs were identified using RIFM fragrance chemicals inventory clustering and read-across search criteria (Date et al., 2020). These criteria are in compliance with the strategy for structuring and reporting a read-across prediction of toxicity as described in Schultz et al. (2015) and are consistent with the guidance provided by OECD within Integrated Approaches for Testing and Assessment (OECD, 2015) and the European Chemical Agency read-across assessment framework (ECHA, 2017b).

- First, materials were clustered based on their structural similarity. Second, data availability and data quality on the selected cluster were examined. Third, appropriate read-across analogs from the cluster were confirmed by expert judgment.
- Tanimoto structure similarity scores were calculated using FCFC4 fingerprints (Rogers and Hahn, 2010).
- The physical-chemical properties of the target material and the read-across analogs were calculated using EPI Suite (US EPA, 2012a).

- **National Library of Medicine's Toxicology Information Services:** <https://toxnet.nlm.nih.gov/>
- **IARC:** <https://monographs.iarc.fr>
- **OECD SIDS:** <https://hpvchemicals.oecd.org/ui/Default.aspx>
- **EPA ACToR:** <https://actor.epa.gov/actor/home.xhtml>
- **US EPA ChemView:** <https://chemview.epa.gov/chemview/>
- **Japanese NITE:** https://www.nite.go.jp/en/chem/chrip/chrip_search/systemTop
- **Japan Existing Chemical Data Base (JECDB):** http://dra4.nihs.go.jp/mhlw_data/jsp/SearchPageENG.jsp
- **Google:** <https://www.google.com>
- **ChemIDplus:** <https://chem.nlm.nih.gov/chemidplus/>





Search keywords: CAS number and/or material names.

*Information sources outside of RIFM's database are noted as appropriate in the safety assessment. This is not an exhaustive list. The links listed above were active as of 10/10/22.

Declaration of competing interest

The authors declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper. We wish to confirm that there are no known conflicts of interest associated with this publication and there has been no significant financial support for this work that could have influenced its outcome. RIFM staff are employees of the Research Institute for Fragrance Materials, Inc. (RIFM). The Expert Panel receives a small honorarium for time spent reviewing the subject work.

- J_{\max} values were calculated using RIFM's skin absorption model (SAM). The parameters were calculated using the consensus model (Shen et al., 2014).
- DNA binding, mutagenicity, genotoxicity alerts, and oncologic classification predictions were generated using the OECD QSAR Toolbox v4.5 (OECD, 2021).
- ER binding and repeat dose categorization were generated using the OECD QSAR Toolbox v4.5 (OECD, 2021).
- Developmental toxicity was predicted using CAESAR v2.1.7 (Cassano et al., 2010), and skin sensitization was predicted using Toxtree v2.6.13.
- Protein binding was predicted using OECD QSAR Toolbox v4.5 (OECD, 2021).
- The major metabolites for the target material and read-across analogs were determined and evaluated using the OECD QSAR Toolbox v4.5 (OECD, 2021).
- To keep continuity and compatibility with *in silico* alerts, OECD QSAR Toolbox v4.5 was selected as the alert system.

	Target Material	Read-across Material	Read-across Material	Read-across Material
Principal Name	Guaiacyl phenylacetate	Guaiacol	Phenylacetic acid	2-Hydroxyphenylacetic acid
CAS No.	4112-89-4	90-05-1	103-82-2	614-75-5
Structure				
Similarity (Tanimoto Score)		0.29	0.43	0.49
SMILES	COc1ccccc1OC(=O)Cc1ccccc1	COc1ccccc1O	OC(=O)Cc1ccccc1	OC(=O)Cc1ccccc1O
Endpoint		Genotoxicity	Genotoxicity (Mutagenicity)	Genotoxicity (Clastogenicity)
Molecular Formula	C ₁₅ H ₁₄ O ₃	C ₇ H ₈ O ₂	C ₈ H ₈ O ₂	C ₈ H ₈ O ₃
Molecular Weight (g/mol)	242.274	124.139	136.15	152.149
Melting Point (°C, EPI Suite)	101.27	32.00	76.50	148.00
Boiling Point (°C, EPI Suite)	343.61	205.00	265.50	240.00
Vapor Pressure (Pa @ 25°C, EPI Suite)	4.51E-03	1.37E+01	5.07E-01	1.45E-01
Water Solubility (mg/L, @ 25°C, WSKOW v1.42 in EPI Suite)	3.40E+01	1.87E+04	1.66E+04	1.32E+05
Log KOW	3.38	1.32	1.41	0.85
J_{\max} (µg/cm²/h, SAM)	0.67	266.39	201.12	404.58
Henry's Law (Pa·m³/mol, Bond Method, EPI Suite)	3.14E-02	1.22E-01	4.15E-03	4.66E-07
Genotoxicity				
DNA Binding (OASIS v1.4, QSAR Toolbox v4.5)	No alert found	No alert found	No alert found	No alert found
DNA Binding (OECD QSAR Toolbox v4.5)	Michael addition Michael addition >> P450-Mediated Activation to Quinones and Quinone-type Chemicals Michael addition >> P450-Mediated Activation to Quinones and Quinone-type Chemicals >> Arenes	Michael addition Michael addition >> P450-Mediated Activation to Quinones and Quinone-type Chemicals Michael addition >> P450-Mediated Activation to Quinones and Quinone-type Chemicals >> Hydroquinones	Michael addition Michael addition >> P450-Mediated Activation to Quinones and Quinone-type Chemicals Michael addition >> P450-Mediated Activation to Quinones and Quinone-type Chemicals >> Arenes	No alert found
Carcinogenicity (ISS)	No alert found	No alert found	No alert found	No alert found
DNA Binding (Ames, MN, CA, OASIS v1.1)	No alert found	No alert found	No alert found	No alert found
In Vitro Mutagenicity (Ames, ISS)	No alert found	No alert found	No alert found	No alert found
In Vivo Mutagenicity (Micronucleus, ISS)	H-acceptor-path3-H-acceptor	H-acceptor-path3-H-acceptor	No alert found	No alert found
Oncologic Classification	Not classified	Phenol-type Compounds	Not classified	Phenol-type Compounds
Metabolism				
Rat Liver S9 Metabolism Simulator and Structural Alerts for Metabolites (OECD QSAR Toolbox v4.5)	See Supplemental Data 1	See Supplemental Data 2	See Supplemental Data 3	See Supplemental Data 4

Summary

There are insufficient toxicity data on guaiacyl phenylacetate (CAS # 4112-89-4). Hence, *in silico* evaluation was conducted to determine read-across analogs for this material. Based on structural similarity, reactivity, metabolism data, physical–chemical properties, and expert judgment, guaiacol (CAS # 90-05-1), phenylacetic acid (CAS # 103-82-2), and 2-hydroxyphenylacetic acid (CAS # 614-75-5) were identified as read-across analogs with sufficient data for toxicological evaluation.

Metabolism

The metabolism of the target material, guaiacyl phenylacetate (CAS # 4112-89-4), was predicted using the Rat Liver S9 Metabolism Simulator (OECD QSAR Toolbox v4.5). The target material is predicted to be metabolized to guaiacol (CAS # 90-05-1) and phenylacetic acid (CAS # 103-82-2) in the first step with 0.339 pre-calculated and 0.95 intrinsic probability. Hence, guaiacol (CAS # 90-05-1) and phenylacetic acid (CAS # 103-82-2) can be used as read-across analogs for the target material. Read-across analogs guaiacol (CAS # 90-05-1), phenylacetic acid (CAS # 103-82-2), and 2-hydroxyphenylacetic acid (CAS # 614-75-5) were out of domain for the *in vivo* rat and the *in vitro* rat S9 simulator (OASIS TIMES v2.30.1.11). However, based on expert judgment, the model's domain exclusion was overridden, and a justification is provided.

Conclusions

- Read-across alcohol guaiacol (CAS # 90-05-1) and read-across acids phenylacetic acid (CAS # 103-82-2) and 2-Hydroxyphenylacetic acid (CAS # 614-75-5) are used as analogs for the target ester, guaiacyl phenylacetate (CAS # 4112-89-4), for the genotoxicity endpoint.
 - o The products of ester hydrolysis (corresponding alcohol and acid) and an analog material to the ester hydrolysis products are used as read-across materials for the target ester for the endpoints indicated in the table.
 - o The read-across materials are major metabolites or analogs of the major metabolites of the target.
 - o Structural differences between the target material and the read-across analogs are mitigated by the fact that the target could be metabolically hydrolyzed to the read-across analogs. Therefore, the toxicity profile of the target is expected to be similar to that of its metabolites.
 - o The target material and the read-across analog have similar physical–chemical properties. Any differences in the physical–chemical properties of the target material and the read-across analogs are toxicologically insignificant.
 - o According to the QSAR OECD Toolbox v4.5, structural alerts for the endpoints evaluated are consistent between the target material and the read-across analog.
 - o The structural alerts for the endpoints evaluated are consistent between the metabolites of the read-across analog and the target material.

References

- Api, A.M., Belsito, D., Bruze, M., Cadby, P., Calow, P., Dagli, M.L., Dekant, W., Ellis, G., Fryer, A.D., Fukayama, M., Griem, P., Hickey, C., Kromidas, L., Lalko, J.F., Liebler, D.C., Miyachi, Y., Politano, V.T., Renskers, K., Ritacco, G., Salvito, D., Schultz, T.W., Sipes, I.G., Smith, B., Vitale, D., Wilcox, D.K., 2015. Criteria for the Research Institute for fragrance materials, Inc. (RIFM) safety evaluation process for fragrance ingredients. *Food Chem. Toxicol.* 82, S1–S19.
- Carthew, P., Clapp, C., Gutsell, S., 2009. Exposure based waiving: the application of the toxicological threshold of concern (TTC) to inhalation exposure for aerosol ingredients in consumer products. *Food Chem. Toxicol.* 47 (6), 1287–1295.
- Cassano, A., Manganaro, A., Martin, T., Young, D., Piclin, N., Pintore, M., Bigoni, D., Benfenati, E., 2010. CAESAR models for developmental toxicity. *Chem. Cent. J.* (4 Suppl. 1), S4.
- Comiskey, D., Api, A.M., Barratt, C., Daly, E.J., Ellis, G., McNamara, C., O'Mahony, C., Robison, S.H., Safford, B., Smith, B., Tozer, S., 2015. Novel database for exposure to fragrance ingredients in cosmetics and personal care products. *Regul. Toxicol. Pharmacol.* 72 (3), 660–672.
- Comiskey, D., Api, A.M., Barrett, C., Ellis, G., McNamara, C., O'Mahony, C., Robison, S. H., Rose, J., Safford, B., Smith, B., Tozer, S., 2017. Integrating habits and practices data for soaps, cosmetics and air care products into an existing aggregate exposure model. *Regul. Toxicol. Pharmacol.* 88, 144–156.
- Cottrez, F., Boitel, E., Ourlin, J.C., Peiffer, J.L., et al., 2016. A 3D reconstituted epidermis based model for quantifying chemical sensitization potency: reproducibility and predictivity results from an inter-laboratory study. *Toxicol. Vitro* 32, 248–260. Apr.
- Date, M.S., O'Brien, D., Botelho, D.J., Schultz, T.W., et al., 2020. Clustering a chemical inventory for safety assessment of fragrance ingredients: identifying read-across analogs to address data gaps. *Chem. Res. Toxicol.* 33 (7), 1709–1718, 2020.
- ECHA, 2011. Guaiacol Registration Dossier. Retrieved from. <https://echa.europa.eu/registration-dossier/-/registered-dossier/9979/1/2>.
- ECHA, 2017a. Guidance on Information Requirements and Chemical Safety Assessment. Chapter R.11: PBT Assessment. Retrieved from. <https://echa.europa.eu/en/web/guest/guidance-documents/guidance-on-information-requirements-and-chemical-safety-assessment>.
- ECHA, 2017b. Read-across Assessment Framework (RAAF). Retrieved from. www.echa.europa.eu/documents/10162/13628/raaf_en.pdf.
- Forreryd, A., Zeller, K.S., Lindberg, T., Johansson, H., Linstedt, M., 2016. From genome-wide arrays to tailor-made biomarker readout - progress towards routine analysis of skin sensitizing chemicals with GARD. *Toxicol. Vitro* 37, 178–188.
- Henry, B., Foti, C., Alsante, K., 2009. Can light absorption and photostability data be used to assess the photosafety risks in patients for a new drug molecule? *J. Photochem. Photobiol. B Biol.* 96 (1), 57–62.
- IFRA (International Fragrance Association), 2019. Volume of Use Survey, January–December 2019.
- Kroes, R., Renwick, A.G., Feron, V., Galli, C.L., Gibney, M., Greim, H., Guy, R.H., Lhuguenot, J.C., van de Sandt, J.J.M., 2007. Application of the threshold of toxicological concern (TTC) to the safety evaluation of cosmetic ingredients. *Food Chem. Toxicol.* 45 (12), 2533–2562.
- Laufersweiler, M.C., Gadagbui, B., Baskerville-Abraham, I.M., Maier, A., Willis, A., et al., 2012. Correlation of chemical structure with reproductive and developmental toxicity as it relates to the use of the threshold of toxicological concern. *Regul. Toxicol. Pharmacol.* 62 (1), 160–182.
- Na, M., Ritacco, G., O'Brien, D., Lavelle, M., Api, A., Basketter, D., 2021. Fragrance skin sensitization evaluation and human testing: 30-year experience. *Dermatitis* 32 (5), 339–352, 2021 Sep–Oct 01.
- OECD, 2015. *Guidance Document on the Reporting of Integrated Approaches to Testing and Assessment (IATA)*. ENV/JM/HA, 2015, p. 7. Retrieved from. <http://www.oecd.org/>.
- OECD, 2021. The OECD QSAR Toolbox, v3.2–4.5. Retrieved from. <http://www.qsartoolbox.org/>.
- RIFM (Research Institute for Fragrance Materials, Inc.), 1983. Mutagenicity Evaluation of Phenylacetic Acid in the Ames Salmonella/microsome Plate Test. Private Communication to FEMA. RIFM, Woodcliff Lake, NJ, USA. Unpublished report from Lorillard Tobacco Company. RIFM report number 36393.
- RIFM (Research Institute for Fragrance Materials, Inc.), 1993. Chromosome Aberrations of Ortho-Hydroxyphenylacetic Acid in Chinese Hamster Ovary (CHO) Cells. RIFM, Woodcliff Lake, NJ, USA. Report to RIFM. RIFM report number 29162.
- RIFM (Research Institute for Fragrance Materials, Inc.), 2022. Exposure Survey. 34. January 2022.
- Roberts, D.W., Api, A.M., Safford, R.J., Lalko, J.F., 2015. Principles for identification of high potency category chemicals for which the dermal sensitization threshold (DST) approach should not be applied. *Regul. Toxicol. Pharmacol.* 72 (3), 683–693.
- Roberts, D.W., Patlewicz, G., Kern, P.S., Gerberick, F., Kimber, I., Dearman, R.J., Ryan, C. A., Basketter, D.A., Aptula, A.O., 2007. Mechanistic applicability domain classification of a local lymph node assay dataset for skin sensitization. *Chem. Res. Toxicol.* 20 (7), 1019–1030.
- Rogers, D., Hahn, M., 2010. Extended-connectivity fingerprints. *J. Chem. Inf. Model.* 50 (5), 742–754.
- Safford, B., Api, A.M., Barratt, C., Comiskey, D., Daly, E.J., Ellis, G., McNamara, C., O'Mahony, C., Robison, S., Smith, B., Thomas, R., Tozer, S., 2015b. Use of an aggregate exposure model to estimate consumer exposure to fragrance ingredients in personal care and cosmetic products. *Regul. Toxicol. Pharmacol.* 72, 673–682.
- Safford, B., Api, A.M., Barratt, C., Comiskey, D., Ellis, G., McNamara, C., O'Mahony, C., Robison, S., Rose, J., Smith, B., Tozer, S., 2017. Application of the expanded Creme RIFM consumer exposure model to fragrance ingredients in cosmetic, personal care and air care products. *Regul. Toxicol. Pharmacol.* 86, 148–156.
- Safford, R.J., 2008. The dermal sensitisation threshold-A TTC approach for allergic contact dermatitis. *Regul. Toxicol. Pharmacol.* 51 (2), 195–200.
- Safford, R.J., Api, A.M., Roberts, D.W., Lalko, J.F., 2015a. Extension of the dermal sensitization threshold (DST) approach to incorporate chemicals classified as reactive. *Regul. Toxicol. Pharmacol.* 72 (3), 694–701.

- Safford, R.J., Aptula, A.O., Gilmour, N., 2011. Refinement of the dermal sensitisation threshold (DST) approach using a larger dataset and incorporating mechanistic chemistry domains. *Regul. Toxicol. Pharmacol.* 60 (2), 218–224.
- Salvito, D.T., Senna, R.J., Federle, T.W., 2002. A Framework for prioritizing fragrance materials for aquatic risk assessment. *Environ. Toxicol. Chem.* 21 (6), 1301–1308.
- Schultz, T.W., Amcoff, P., Berggren, E., Gautier, F., Klaric, M., Knight, D.J., Mahony, C., Schwarz, M., White, A., Cronin, M.T., 2015. A strategy for structuring and reporting a read-across prediction of toxicity. *Regul. Toxicol. Pharmacol.* 72 (3), 586–601.
- Shen, J., Kromidas, L., Schultz, T., Bhatia, S., 2014. An *in silico* skin absorption model for fragrance materials. *Food Chem. Toxicol.* 74, 164–176.
- US EPA, 2012a. Estimation Programs Interface Suite for Microsoft Windows, v4.0–v4.11. United States Environmental Protection Agency, Washington, DC, USA.
- US EPA, 2012b. The ECOSAR (ECOLOGICAL Structure Activity Relationship) Class Program for Microsoft Windows, v2.0. United States Environmental Protection Agency, Washington, DC, USA.